Objective of pharmacologic vitreolysis.

Area of Science:

• Ophthalmology
• Retinal Science
• Pharmacology

Background:

• Mechanical vitrectomy often leaves residual cortical vitreous, leading to vitreoretinal traction and potential surgical failure.
• Current surgical methods can cause iatrogenic damage to the macula due to mechanical manipulation.
• Retinal diseases with fibrovascular proliferation benefit from treatments that prevent advanced stages.

Purpose of the Study:

• To achieve pharmacologic vitreolysis by cleaving the vitreoretinal junction and liquefying the vitreous gel.
• To explore the benefits of pharmacologic vitreolysis as a less traumatic alternative to mechanical vitrectomy.
• To investigate the potential of pharmacologic vitreolysis in managing retinal diseases characterized by vitreoretinal interface abnormalities.

Main Methods:

• Inducing posterior vitreous detachment (PVD) through pharmacologic agents.
• Liquefying vitreous gel to reduce vitreoretinal traction.
• Intravitreal injection as a less invasive treatment modality.

Main Results:

• Pharmacologic vitreolysis achieves complete PVD without mechanical manipulation, minimizing macular damage.
• The approach offers a less traumatic alternative to vitrectomy, potentially beneficial for prophylactic treatment.
• Cleavage of the cortical hyaloid improves retinal oxygen supply and may interfere with hypoxia-driven pathways.

Conclusions:

• Pharmacologic vitreolysis provides a complete PVD and vitreous liquefaction, addressing limitations of mechanical vitrectomy.
• This method reduces the risk of iatrogenic damage and may serve as a prophylactic treatment for proliferative retinopathies.
• Altered molecular flux and improved oxygenation are key mechanisms impacting retinal hypoxia and vasoactive factor expression.